

ACR Suggested Reading List

Rheumatoid Arthritis

1. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum.* 2005 Nov;52(11):3381-90. PubMed PMID: 16258899.
 - a. Initial trial demonstrating value of up-front therapy in early RA.
2. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet.* 2002 Apr 6;359(9313):1173-7. PubMed PMID: 11955534.
 - a. Recent CIRT trial showed no benefit to MTX for primary prevention of CVD, but what about in RA?
3. Grigor C, Capell H, Stirling A, McMahon AD, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet.* 2004 Jul 17-23;364(9430):263-9. PubMed PMID: 15262104.
 - a. RA should be treated early and aggressively.
4. van Vollenhoven RF, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med.* 2012 Aug 9;367(6):508-19. PubMed PMID: 22873531.
 - a. JAK inhibitors an oral option for RA, numerically but not significantly better than TNF inhibitors
5. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis.* 2017 May;76(5):840-847. PMID: 27856432
 - a. IL6 inhibition is likely superior to TNF – similar results in ADACTA for tocilizumab
6. Raaschou P, Söderling J, Turesson C, et al. Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study. *Ann Intern Med.* 2018 Sep 4;169(5):291-299. PMID: 30105374.
 - a. TNF inhibitors are not associated with increased risk for malignancy recurrence
7. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N Engl J Med.* 2017 Feb 16;376(7):652-662. PMID: 28199814.
 - a. JAK inhibitors with benefit over PLBO – similar results in more recent SELECT-COMPARE study with upadacitinib
8. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum.* 2012 Sep;64(9):2824-35. PMID: 22508468
 - a. In an age of fancy biologics, triple therapy is still an option.

Gout

9. White WB, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. *N Engl J Med.* 2018 Mar 29;378(13):1200-1210. PMID: 29527974.
 - a. Febuxostat w/higher rate of cardiovascular events than allopurinol, though no placebo and unclear whether it is better or worse than nothing
10. Taylor TH, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. *Am J Med.* 2012 Nov;125(11):1126-1134.e7. PubMed PMID: 23098865.
 - a. Starting allopurinol does not precipitate or prolong acute gout attacks in a cohort with aggressive prophylaxis
11. Vargas-Santos AB, Peloquin CE, Zhang Y, et al. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. *JAMA Intern Med.* 2018 Nov 1;178(11):1526-1533. PMID: 30304329.
 - a. Allopurinol is not associated with renal dysfunction
12. Stamp LK, Taylor WJ, Jones PB. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum.* 2012 Aug;64(8):2529-36. PMID: 22488501.
 - a. Nice case-control study (almost an oxymoron) demonstrating value of starting low in CKD

If you would like to download the papers themselves, they are available: <https://tinyurl.com/y4af7472>

ACR Suggested Reading List

Vasculitis

13. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010 Jul 15;363(3):221-32. PMID: 20647199.
 - a. RAVE trial demonstrating non-inferiority of Rituxan vs. Cytoxan in induction for ANCA vasculitis
14. Stone JH, et al. Trial of Tocilizumab in Giant-Cell Arteritis. *N Engl J Med*. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849. PMID:28745999.
 - a. GIACTA trial demonstrating efficacy of IL6 inhibition in giant cell arteritis
15. Guillevin L, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. *N Engl J Med*. 2014 Nov 6;371(19):1771-80. PMID: 25372085.
 - a. MAINRITSAN trail demonstrating superiority of Rituxan over Imuran for maintenance of remission in ANCA vasculitis
16. Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *N Engl J Med*. 2017 May 18;376(20):1921-1932. PMID: 28514601.
 - a. IL5 inhibition works for asthmatic symptoms of EGPA
17. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med*. 2005 Jan 27;352(4):351-61. PMID: 15673801.
 - a. Classic in GCA – indicated that TNF likely not beneficial

Osteoarthritis

18. Krebs EE, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. *JAMA*. 2018 Mar 6;319(9):872-882. PMID: 29509867
 - a. SPACE RCT demonstrating no benefit of opioid therapy over non-opioid therapy
19. McAlindon TE, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. *JAMA*. 2017 May 16;317(19):1967-1975. PMID: 28510679.
 - a. RCT evaluating intraarticular steroid injections in osteoarthritis of the knee
20. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *N Engl J Med*. 2016 Dec 29;375(26):2519-29. PMID: 27959716.
 - a. Celecoxib noninferior from CVD perspective than nonselectives; lower rates of GIB and renal dx
21. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. *Nat Rev Dis Primers*. 2016 Oct 13;2:16072. PMID: 27734845.
 - a. Great review of osteoarthritis – recommend other nature reviews as well

Osteoporosis / Metabolic Bone Disease

22. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*. 2009 Aug 20;361(8):756-65. PMID: 19671655.

Psoriatic Arthritis

23. Mease PJ, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial. *Arthritis Rheumatol*. 2019 Feb 12. PubMed PMID: 30747501.
 - a. SEAM study demonstrating etanercept superior to MTX both as combo or monotherapy but that MTX also seems to work reasonably well by itself

If you would like to download the papers themselves, they are available: <https://tinyurl.com/y4af7472>

ACR Suggested Reading List

24. McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015 Sep 19;386(9999):1137-46. PMID: 26135703.
 - a. FUTURE2 demonstrating IL17 efficacy in psoriatic arthritis
25. Gladman D, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. *N Engl J Med*. 2017 Oct 19;377(16):1525-1536. PMID: 29045207.
 - a. JAK inhibitors also an option for psoriatic arthritis
26. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. *Lancet*. 2015 Dec 19;386(10012):2489-98. PMID: 26433318.
 - a. As in RA, tight control improves outcomes in psoriatic arthritis

Pediatric Rheumatology

27. Ravelli A, Minoia F, Davi S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis*. 2016 Mar;75(3):481-9. PMID: 26865703.
 - a. Guidelines for MAS in JIA
28. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. *N Engl J Med*. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160. PMID: 28445659.
 - a. Adalimumab effective in uveitis
29. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken)*. 2011 Apr;63(4):465-82. PMID: 21452260.
 - a. Helpful guidelines for treatment of JIA

Ankylosing Spondylitis

30. Haroon N, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis Rheum*. 2013 Oct;65(10):2645-54. PMID: 23818109
 - a. TNF inhibitors appear to reduce radiographic progression in ankylosing spondylitis
31. Baeten D, Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med*. 2015 Dec 24;373(26):2534-48. PMID: 26699169.
 - a. IL17 demonstrated benefit in ankylosing spondylitis

Scleroderma

32. Steen VD, et al. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. *Arthritis Rheum*. 1998 Sep;41(9):1613-9. PMID: 9751093.
 - a. Case control study suggesting risk of scleroderma renal crisis in patients with scleroderma who receive steroids
33. Sullivan KM, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. *N Engl J Med*. 2018 Jan 4;378(1):35-47. PMID: 29298160.
 - a. SCOT trial demonstrating benefit of stem cell transplant in scleroderma
34. Tashkin DP, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N. Engl. J. Med.* (2006) 354(25):2655-2666. PMID: 17302533.
 - a. Modest benefit to skin and pulmonary disease for Cytoxan over placebo

If you would like to download the papers themselves, they are available: <https://tinyurl.com/y4af7472>

ACR Suggested Reading List

35. Tashkin DP, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med*. 2016 Sep;4(9):708-719. PMID: 27469583.
 - a. Mycophenolate mofetil non-inferior to Cytoxan for scleroderma pulmonary disease
36. Herrick AL. Management of Raynaud's phenomenon and digital ischemia. *Curr Rheumatol Rep*. 2013 Jan;15(1):303. doi: 10.1007/s11926-012-0303-1. Review. PMID: 23292819.
 - a. Nice review of the management of Raynaud's syndrome. Essential for scleroderma clinic.
37. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*. 2017 Aug;76(8):1327-1339. PMID: 27941129.
 - a. Updated recommendations for management of systemic sclerosis.

Lupus

38. Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol*. 2009 May;20(5):1103-12 PMID: 19369404
 - a. ALMS trial demonstrating noninferiority of mycophenolate mofetil vs. Cytoxan
39. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. *N Engl J Med*. 1991 Jan 17;324(3):150-4. PMID: 1984192.
 - a. High rate of flares in patients with SLE who discontinue HCQ
40. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011 Feb 26;377(9767):721-31. PMID: 21296403.
 - a. BLISS inhibitor belimumab effective in SLE
41. Abeles AM, et al. The clinical utility of a positive antinuclear antibody test result. *Am J Med*. 2013 Apr;126(4):342-8. PMID: 23395534
 - a. A positive ANA does not mean your patient has lupus, even at high titers and even with symptoms
42. van Vollenhoven RF, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. *Lancet*. 2018 Oct 13;392(10155):1330-1339.
 - a. Early study demonstrating possible benefit of IL12/23 for SLE, Phase III coming.
43. Andreoli L, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Ann Rheum Dis*. 2017 Mar;76(3):476-485. PMID: 27457513
 - a. Good review of family planning for SLE
44. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. *JAMA Ophthalmol*. 2014;132(12):1453-60.
 - a. Observational study that touched off controversy regarding: dosing of hydroxychloroquine
45. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood*. 2018 Sep 27;132(13):1365-1371. PMID: 30002145.
 - a. Rivaroxaban associated with markedly higher risk of VTE than coumadin in APLS
46. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med*. 2003 Oct 16;349(16):1526-33. PMID: 14561795.
 - a. Classic study on military recruits demonstrating autoantibody formation during pre-clinical phase

Myositis

47. Oddis CV, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis Rheum*. 2013 Feb;65(2):314-24. PMID: 23124935

If you would like to download the papers themselves, they are available: <https://tinyurl.com/y4af7472>

ACR Suggested Reading List

- a. Rituximab not superior to placebo over 8-week RCT, but most patients benefit in observational phase of trial
- 48. Bottai M, et al. International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) . EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017 Nov 14;3(2):e000507. PMID: 29177080.
 - a. New myositis classification criteria

Sjogrens Syndrome

- 49. Gottenberg JE, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58. PubMed PMID: 25027140.
 - a. No benefit to HCQ for Sjogrens syndrome in 24 week RCT portion of trial, but some patients improved after unblinding

Miscellany

- 50. Rodríguez-Pintó I, et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford). 2018 Apr 11. PMID: 29660074.
 - a. Triple therapy associated with greater survival in catastrophic antiphospholipid syndrome
- 51. Battafarano DF, et al. 2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015-2030. Arthritis Care Res (Hoboken). 2018 Apr;70(4):617-626. PMID: 29400009.
 - a. Increasing prevalence of rheumatologic disease and decrease in providers may cause shortage
- 52. Duarte-García A, et al. The Evidence Basis for the American College of Rheumatology Practice Guidelines. JAMA Intern Med. 2018 Jan 1;178(1):146-148. PubMed PMID: 29181496.
 - a. Many ACR guidelines based on low quality evidence, but similar to other specialties
- 53. Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol. 2018 Sep;70(9):1399-1407. PMID: 29623679.
 - a. Certolizumab safe in pregnancy
- 54. Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013 Dec 26;369(26):2515-24. PMID: 24369076.
 - a. Partial meniscectomy no better than sham surgery for meniscal tears
- 55. Triplett JD, Buzzard KA, Lubomski M, et al. Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). J Neurol Neurosurg Psychiatry. 2019 Mar 9. PubMed PMID: 30852493.
 - a. The BEE syndromes! Good review of neuro presentations in our realm
- 56. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002 Jan 2;287(1):92-101. Review. PubMed PMID: 11754714.
 - a. Old school article with a good review of NPV, PPV, and likelihood ratios
- 57. Rhon DI, Boyles RB, Cleland JA. One-year outcome of subacromial corticosteroid injection compared with manual physical therapy for the management of the unilateral shoulder impingement syndrome: a pragmatic randomized trial. Ann Intern Med. 2014 Aug 5;161(3):161-9. PMID: 25089860.
 - a. CSI for shoulder impingement is not beneficial
- 58. Margaretten ME, Kohlwes J, Moore D, et al. Does this adult patient have septic arthritis? JAMA. 2007 Apr 4;297(13):1478-88. Review. PMID: 17405973.
 - a. Old school, common problem.

If you would like to download the papers themselves, they are available: <https://tinyurl.com/y4af7472>